嵌合抗原受体T细胞对B细胞淋巴瘤的作用研究  

Study on the role of T CAR cells in B cell lymphoma

作　　者：刘茜[1,2] 赖洵[2] 程新[1,2] 高小丽[2] 吴亚运[2] 

机构地区：[1]昆明理工大学医学院,昆明650000 [2]昆明理工大学附属云南省第一人民医院血液科,昆明650000

出　　处：《生命的化学》2016年第5期661-665,共5页Chemistry of Life

基　　金：云南省科技计划项目(2012FB203);云南省卫生科技计划项目(2012WS0064)

摘　　要：过继性免疫治疗(adoptive cellular immunotherapy,ACI)是将供体的淋巴细胞转移给受体,增强其细胞免疫功能。这种治疗是目前较为有效的恶性肿瘤的治疗方法之一,已在实体瘤和血液肿瘤的临床治疗中取得较好疗效。近年来发展的嵌合抗原受体(chimeric antigen receptor,CAR)T细胞是利用基因技术改造得来的,它表达肿瘤特异性,并显示出靶向性、杀伤活性和持久性,这为过继性细胞免疫治疗注入了新的解决方案。CAR发展到现在共经历过三代改进,前人也就每代CAR进行了大量临床试验,得出对临床治疗具有现实意义的实验结果。本文就CAR技术对B细胞淋巴瘤的作用影响作一综述。Adoptive cellular immunotherapy（ACI） is a kind of treatment methods that will transfer the donor lymphocytes to the receptors in order to enhance the cellular immune function. At present, it has been one of the more effective methods of treating malignant tumors, and it has achieved good therapeutic effect in the clinical treatment of solid tumors and hematological malignancy. In recent years, developmental CAR-T cells which are transformed by genetically modified technology and expressed tumor specificity that displayed the targeting property, killing activity and persistence. It has injected new solutions for adoptive cellular immunotherapy. Now CAR has experienced three generations of improvement. A large number of clinical trials have been carried out on each generation of CAR, and the experimental results are of practical significance to clinical treatment. In this paper, we will introduce the effect and influence of CAR technology to treat B-cell lymphoma.

关 键 词：过继性免疫治疗 嵌合抗原受体 淋巴细胞 B细胞淋巴瘤 

分 类 号：R733.1[医药卫生—肿瘤]